Sjögren’s, Scleroderma and a “Mild” PH Label: Why Beijing Keeps Coming Up

Disclaimer: This post reflects one person’s analysis of public patient case discussions, not personalized medical advice or a formal treatment plan. All clinical decisions remain the full responsibility of your in-person treating rheumatology team. No medical referral is implied or offered here.

“China is cheap” — true, and the least interesting part

Search for autoimmune disease treatment in China, and you’ll see “affordable” everywhere. That’s not the reason people book the flight. Two far more meaningful, underdiscussed drivers keep surfacing in global patient threads:

• Top specialized teams here run the same high-volume workup cycles week after week: right heart catheterizations, interstitial lung disease fibrosis reads, and targeted biologic initiations. That consistent, repeated volume builds a clinical instinct no medical lecture hall can teach.
• A small set of autoimmune therapies reach Beijing clinics months to years before they become widely available in other regions. Telitacicept for Sjögren’s syndrome is the one patients now ask about quietly — not because it costs less, but because the treatment door opened here first.

That’s the part no generic medical tourism brochure ever mentions.

That public-thread case — and exactly what I’m sharing here

A patient recently posted a public case summary with these details: diffuse scleroderma, Scl-70 positive, NSIP-type lung scarring, FVC around 38%, already on MMF and tadalafil — with one single, unquantified line reading “mild pulmonary hypertension” with no pressure numbers attached.

Reading only the public, shared details, the disease profile is fully consistent. The only open, unconfirmed variable is that unnumbered “mild PH” line.

Two distinct clinical paths for unquantified “mild PH” in scleroderma

In scleroderma, an unspecified “mild PH” almost always splits into two distinct clinical paths, with almost no overlapping drug strategies:

• If the pulmonary vessels themselves are failing (Group 1 PAH): PAH-targeted therapy becomes a core part of the care plan
• If scar-tissue hypoxia is driving elevated pressure (Group 3 PH): PAH-specific drugs rarely deliver benefit, and can add unnecessary fluid retention or liver load. The priority here is optimized anti-fibrotic therapy, paired with oxygen support and pulmonary rehabilitation.

An echocardiogram can narrow the possibilities, but a formal right heart catheterization is the only test that settles the diagnosis definitively. Until you have actual, measured pressure numbers, that “mild PH” line is a critical red flag — not a clear treatment roadmap.

Two trusted Beijing clinical centers for this exact patient profile

Two trusted Beijing clinical desks that regularly cross-reference this exact patient profile:

• ‌PUMCH International Medical Services‌: The highest-volume center in mainland China for CTD-PAH and right heart catheterization procedures, and the strongest local team to evaluate whether to maintain MMF therapy or step up immunosuppression.
• ‌China-Japan Friendship International Medical Center‌: Home to the National Center for Respiratory Medicine, with unmatched expertise in HRCT NSIP pattern re-reading, nintedanib vs MMF treatment decision-making, pulmonary rehabilitation, and pre-transplant workup.

Bring all your existing records: full echocardiogram reports, complete antibody panels, HRCT scans (DICOM files if you have them), and your full current medication list. If any required test is missing to finalize the roster match, it can be completed on-site during your visit. You do not need to forward your entire full medical file before boarding your flight.

One non-negotiable real-world note for patients with FVC at 38%: Check your resting SpO₂ levels before booking any long-haul flight. If your baseline reading sits below ~88%, arrange portable oxygen for the full travel leg. Long-haul cabin hypoxia is the single most common issue that derails these trips, far more than any pharmacy or scheduling barrier. This is a neutral, public-post analysis only — not a clinical consult, not a paid referral pitch. If your home bedside rheumatology team already has an active, progressing care plan in place, that existing plan always takes priority. My role is simply to pre-map your full chart before you arrive, so no one lands in Beijing and has to restart the entire diagnostic puzzle from day one.

Why me — and exactly where my lane stops

I was never formally trained as a rheumatologist. I grew up inside this disease community, the hard way.

My mother lived with connective-tissue disease for years before she passed, when I was eight. Back then, no one used words like Sjögren’s or scleroderma — they called it “collagen disease”, and our entire household care arsenal was eggshell tea and a chipped box of Ciwujia extract sitting by the kitchen sink.

Years later, this same family of illnesses circled back close to home: a Chinese-American colleague of mine received care at UFH Beijing under her international insurance. I joked once that even her clinic cabinet still held traces of those old, familiar home remedies. She passed away at 49.

And one of my closest friends — an immunology master’s graduate who completed advanced rheumatology training at PUMCH, then went on to visiting fellow stints at UCLA and NUI Galway — once told me how many Scl-70 positive scleroderma charts she had reviewed during her years in Beijing. So when I read a chart like this now, I’m not parsing it from random Google search results. I read it the exact way a senior rheumatology team would.

To be 100% clear: I am a patient companion with a clinician-trained eye. I am not your treating physician. I do not diagnose conditions, I do not titrate medication doses, and I never take clinical responsibility for any patient’s care. That full, non-negotiable responsibility always stays with the licensed, in-room treating doctor.

What I actually do (no bundled care contract pitch)

• Pre-landing chart review‌: Send over all your existing records, and I will tell you whether your first week in Beijing should prioritize a repeat HRCT scan first, or schedule your right heart catheterization first. That way, day one in Beijing is not day one of reopening old, already-answered questions.
• ‌Local on-site support at appointment release time‌: The 7-day PUMCH appointment pool is fully public for every patient, including the top specialists you read about online. I do not hold hidden backdoor access, and I cannot lock a slot in advance. What I can do is pre-stage your full records, and monitor the appointment portal the second new slots are released. If a near-week cancellation or last-minute opening appears, you will not be the patient who finds out three days too late. Sometimes that moves a “next month” appointment to “this week”. Sometimes it does not. I will always say that plainly, instead of selling you a promise I cannot keep.
• ‌Roster sense, not name-dropping‌: When a new slot opens, I will tell you clearly whether that week’s on-call attending’s case mix is a perfect match for your Scl-70+/FVC-38% profile — or if they are simply free, with no relevant experience in your specific disease. You get the same tier of board-certified doctor, but matched directly to your lab results and case complexity.
• ‌In-room support, then one-page home summary‌: You lead the full consultation conversation, I follow along to capture every clinical detail. You leave Beijing with a single, clean one-page summary that your home rheumatology team can pick up cold — no extra background context needed, no follow-up calls required to clarify what was discussed.

That is my full lane: same-day, on-the-ground clinical grounding support, not a locked-in long-term care contract.

If you found this page searching for any of these terms

• telitacicept Sjögren’s China for foreigners
• scleroderma + “mild PH” Beijing — is it Group 1 or Group 3
• right heart cath vs HRCT, what order actually makes clinical sense
• PUMCH rheumatology how the 7-day appointment release really works
• dry eyes, unrelenting fatigue, Scl-70 positive, and every return visit bringing back the same unchanged labs

You do not need an overpriced, one-size-fits-all medical tour. You need the right, properly matched clinical door — and someone who learned this illness first at the kitchen table, then re-learned it from the rheumatology lab bench: the kind of person who can tell the difference between a doctor who simply has an empty slot, and a doctor who actually fits your specific chart.

I can never promise you the exact celebrity specialist name you saw posted online. But I can promise you will not spend another full 7-day appointment release cycle waiting on a doctor who only renews your old pills, with zero progress on your unconfirmed PH diagnosis.
And if your own home rheumatologist already has a clear, progressing care plan in place? Keep that plan. This service exists only for the stretches where the clinical know-how is right there in Beijing — but the public appointment calendar is the only thing standing in your way.

All content on this page references publicly available hospital scheduling guidelines and published international rheumatology clinical consensus. Individual treatment outcomes vary by patient. No medical services are offered or implied on this site.